伊布替尼联合利妥昔单抗一线治疗老年套细胞淋巴瘤患者
这项单中心、单臂Ⅱ期试验纳入50例未经治疗的老年(≥65岁)套细胞淋巴瘤患者,采用无化疗的伊布替尼联合利妥昔单抗方案,最佳总缓解率为96%(完全缓解71%),中位随访45个月时中位无进展生存期与总生存期均未达到,3年生存率分别为87%和94%,22%的患者出现3级心房颤动。
要点
- 最佳总缓解率96%,完全缓解率71%,中位无进展生存期与总生存期均未达到。
- 中位随访45个月,3年无进展生存率87%、总生存率94%,无患者在治疗中死亡。
- 22%患者发生3级心房颤动,强烈推荐基线心血管风险评估。
核心结论
- 伊布替尼联合利妥昔单抗方案对老年套细胞淋巴瘤患者有效,强烈推荐进行基线心血管风险评估,需要随机试验才能得出确定性结论。
研究设计与样本
- 单中心、单臂Ⅱ期临床试验(NCT01880567),纳入50例未经治疗的老年(≥65岁)套细胞淋巴瘤患者。
- 排除Ki-67%≥50%及母细胞样形态的患者;伊布替尼联合利妥昔单抗给药至多2年,之后继续伊布替尼单药。
- 主要目标为评估总缓解率与安全性;对可评估样本的基线组织进行全外显子组测序和bulk RNA测序。
主要发现
- 中位年龄71岁(四分位距69-76岁),16%患者为高危简化套细胞淋巴瘤国际预后指数。
- Ki-67%低(<30%)者38例(76%),中等偏高(≥30%-50%)者12例(24%)。
- 最佳总缓解率96%(完全缓解71%);中位随访45个月(四分位距24-56个月)后,28例(56%)患者因各种原因退出研究,包括4例疾病进展、21例毒性、3例其他原因。
- 中位无进展生存期和总生存期均未达到,3年生存率分别为87%和94%;无患者在研究治疗期间死亡。
- 11例(22%)患者发生3级心房颤动,3-4级骨髓抑制见于<5%的患者;与完全缓解患者相比,部分缓解患者中CCND1、BIRC3、BANK1、SETBP1、AXIN2和IL2RA存在差异过表达。
临床怎么用
- 作者认为伊布替尼联合利妥昔单抗方案对老年套细胞淋巴瘤患者有效,并强烈推荐进行基线心血管风险评估。
- 作者指出需要随机试验才能得出确定性结论。
局限性
- 作者指出需要随机试验才能得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously untreated older patients with MCL (age ≥ 65 years). METHODS: We enrolled 50 patients with MCL in this single-institution, single-arm, phase II clinical trial (NCT01880567). Patients with Ki-67% ≥ 50% and blastoid morphology were excluded. Ibrutinib was administered with rituximab up to 2 years with continuation of ibrutinib alone. The primary objective was to assess the overall response rate and safety of IR. In evaluable samples, whole-exome sequencing and bulk RNA sequencing from baseline tissue samples were performed. RESULTS: The median age was 71 years (interquartile range 69-76 years). Sixteen percent of patients had high-risk simplified MCL international prognostic index. The Ki-67% was low (< 30%) in 38 (76%) and moderately high (≥ 30%-50%) in 12 (24%) patients. The best overall response rate was 96% (71% complete response). After a median follow-up of 45 months (interquartile range 24-56 months), 28 (56%) patients came off study for various reasons (including four progression, 21 toxicities, and three miscellaneous reasons). The median progression-free survival and overall survival were not reached, and 3-year survival was 87% and 94%, respectively. None of the patients died on study therapy. Notably, 11 (22%) patients had grade 3 atrial fibrillation. Grade 3-4 myelosuppression was seen in < 5% of patients. Differential overexpression of CCND1, BIRC3, BANK1, SETBP1, AXIN2, and IL2RA was noted in partial responders compared with patients with complete response. CONCLUSION: IR combination is effective in older patients with MCL. Baseline evaluation for cardiovascular risks is highly recommended. Randomized trial is needed for definitive conclusions.
引用
- Jain P, Zhao S, Lee HJ, et al. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2021. PMID: 34797699. doi:10.1200/JCO.21.01797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。